Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort.

[1]  S. Suissa,et al.  Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases , 2018, BMJ Open.

[2]  Eric E. Smith,et al.  Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality , 2018, JAMA.

[3]  D. Rockey,et al.  Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. , 2017, The American journal of medicine.

[4]  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, British Medical Journal.

[5]  Deborah M Caldwell,et al.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, BMJ.

[6]  L. Huiart,et al.  Trends in the prescription of novel oral anticoagulants in UK primary care , 2017, British journal of clinical pharmacology.

[7]  T. Gomes,et al.  Direct Oral Anticoagulant‐ or Warfarin‐Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study , 2017, Chest.

[8]  P. Chan,et al.  Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[9]  C. Sindet-Pedersen,et al.  Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark , 2017, European heart journal.

[10]  J. Beyer-Westendorf,et al.  Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs , 2017, Journal of Gastroenterology.

[11]  F. Pomero,et al.  Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. , 2017, International journal of cardiology.

[12]  G. Lip,et al.  Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis , 2017, Stroke.

[13]  A. Singer,et al.  Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non-Vitamin K Antagonist Oral Anticoagulant. , 2017, The Journal of emergency medicine.

[14]  Gregory Y. H. Lip,et al.  Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in Denmark , 2016, Scientific Reports.

[15]  S. Yusuf,et al.  Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. , 2016, Thrombosis research.

[16]  Z. Goldberger,et al.  National Trends in Ambulatory Oral Anticoagulant Use. , 2015, The American journal of medicine.

[17]  A. Iorio,et al.  Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials , 2015, Journal of thrombosis and haemostasis : JTH.

[18]  Joel Skaistis,et al.  Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis , 2015, PloS one.

[19]  L. Køber,et al.  Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. , 2015, JAMA.

[20]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[21]  Elsebeth Lynge,et al.  The Danish National Patient Register , 2011, Scandinavian journal of public health.

[22]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[23]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[24]  A. Vaag,et al.  Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People , 2008, Circulation.

[25]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.